Yesterday, Alaunos announced financial results for the second quarter and a strategic reprioritization to focus on our promising hunTR® #TCR discovery platform and suspend further drug development under our TCR-T Phase 1/2 clinical trial as we explore broad strategic alternatives for the Company. Alaunos has engaged Cantor Fitzgerald & Co. to act as a strategic advisor for this process. We are proud of the work we’ve done to advance the field’s understanding of TCR-T #celltherapy for driver mutations and continue to believe this approach has the potential to target the heart of #cancer growth. https://lnkd.in/gnFfiMZC
Alaunos Therapeutics
Biotechnology
Houston, Texas 6,731 followers
Attacking solid tumors with TCRs
About us
Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we strike cancer at its core by engineering cell therapies that target neoantigens arising from genomic mutations. We have developed proprietary, rapid, cost-effective solutions to deliver tumor-specific killer T cells to large cancer patient populations with unmet clinical need. We are based in Houston, TX, home to the largest medical center in the world; and in a state with no state income tax and a low cost of living. For more information about Alaunos, please visit www.alaunos.com. Click on the Careers tab of our web page to join our exciting team and help make a difference in the lives of cancer patients and their families.
- Website
-
https://alaunos.com
External link for Alaunos Therapeutics
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Houston, Texas
- Type
- Public Company
Locations
-
Primary
Get directions
8030 El Rio St
Houston, Texas 77054, US